Skip to main content
PMC home page
Thorax logoLink to Thorax
. 2005 Jul;60(7):605–609. doi: 10.1136/thx.2005.042994

Pulmonary hypertension in chronic obstructive pulmonary disease: current theories of pathogenesis and their implications for treatment

J Wright 1, R Levy 1, A Churg 1
PMCID: PMC1747459  PMID: 15994270

Abstract

The development of pulmonary hypertension is a poor prognostic sign in patients with chronic obstructive pulmonary disease (COPD), affecting both mortality and quality of life. Although pulmonary hypertension in COPD is traditionally viewed as a result of emphysematous destruction of the vascular bed and/or hypoxia, recent studies indicate that neither of these factors correlates very well with pulmonary artery pressures. New human and animal experimental data are beginning to show that pulmonary hypertension in this setting is probably a result of the direct effect of tobacco smoke on the intrapulmonary vessels with abnormal production of mediators that control vasoconstriction, vasodilatation, and vascular cell proliferation, ultimately leading to aberrant vascular remodelling and aberrant vascular physiology. These changes are in many ways similar to those seen in other forms of pulmonary hypertension and suggest that the treatments used for primary pulmonary hypertension may be beneficial in patients with COPD.

Full Text

The Full Text of this article is available as a PDF (101.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barberà J. A., Peinado V. I., Santos S. Pulmonary hypertension in chronic obstructive pulmonary disease. Eur Respir J. 2003 May;21(5):892–905. doi: 10.1183/09031936.03.00115402. [DOI] [PubMed] [Google Scholar]
  2. Barst R. J., Rubin L. J., McGoon M. D., Caldwell E. J., Long W. A., Levy P. S. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med. 1994 Sep 15;121(6):409–415. doi: 10.7326/0003-4819-121-6-199409150-00003. [DOI] [PubMed] [Google Scholar]
  3. Biernacki W., Gould G. A., Whyte K. F., Flenley D. C. Pulmonary hemodynamics, gas exchange, and the severity of emphysema as assessed by quantitative CT scan in chronic bronchitis and emphysema. Am Rev Respir Dis. 1989 Jun;139(6):1509–1515. doi: 10.1164/ajrccm/139.6.1509. [DOI] [PubMed] [Google Scholar]
  4. Cooper R., Ghali J., Simmons B. E., Castaner A. Elevated pulmonary artery pressure. An independent predictor of mortality. Chest. 1991 Jan;99(1):112–120. doi: 10.1378/chest.99.1.112. [DOI] [PubMed] [Google Scholar]
  5. Geraci M. W., Gao B., Shepherd D. C., Moore M. D., Westcott J. Y., Fagan K. A., Alger L. A., Tuder R. M., Voelkel N. F. Pulmonary prostacyclin synthase overexpression in transgenic mice protects against development of hypoxic pulmonary hypertension. J Clin Invest. 1999 Jun;103(11):1509–1515. doi: 10.1172/JCI5911. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Giaid A., Yanagisawa M., Langleben D., Michel R. P., Levy R., Shennib H., Kimura S., Masaki T., Duguid W. P., Stewart D. J. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med. 1993 Jun 17;328(24):1732–1739. doi: 10.1056/NEJM199306173282402. [DOI] [PubMed] [Google Scholar]
  7. Hale K. A., Ewing S. L., Gosnell B. A., Niewoehner D. E. Lung disease in long-term cigarette smokers with and without chronic air-flow obstruction. Am Rev Respir Dis. 1984 Nov;130(5):716–721. doi: 10.1164/arrd.1984.130.5.716. [DOI] [PubMed] [Google Scholar]
  8. Hale K. A., Niewoehner D. E., Cosio M. G. Morphologic changes in the muscular pulmonary arteries: relationship to cigarette smoking, airway disease, and emphysema. Am Rev Respir Dis. 1980 Aug;122(2):273–278. doi: 10.1164/arrd.1980.122.2.273. [DOI] [PubMed] [Google Scholar]
  9. He H., Venema V. J., Gu X., Venema R. C., Marrero M. B., Caldwell R. B. Vascular endothelial growth factor signals endothelial cell production of nitric oxide and prostacyclin through flk-1/KDR activation of c-Src. J Biol Chem. 1999 Aug 27;274(35):25130–25135. doi: 10.1074/jbc.274.35.25130. [DOI] [PubMed] [Google Scholar]
  10. Hoshikawa Y., Voelkel N. F., Gesell T. L., Moore M. D., Morris K. G., Alger L. A., Narumiya S., Geraci M. W. Prostacyclin receptor-dependent modulation of pulmonary vascular remodeling. Am J Respir Crit Care Med. 2001 Jul 15;164(2):314–318. doi: 10.1164/ajrccm.164.2.2010150. [DOI] [PubMed] [Google Scholar]
  11. Kessler R., Faller M., Weitzenblum E., Chaouat A., Aykut A., Ducoloné A., Ehrhart M., Oswald-Mammosser M. "Natural history" of pulmonary hypertension in a series of 131 patients with chronic obstructive lung disease. Am J Respir Crit Care Med. 2001 Jul 15;164(2):219–224. doi: 10.1164/ajrccm.164.2.2006129. [DOI] [PubMed] [Google Scholar]
  12. Kubo K., Ge R. L., Koizumi T., Fujimoto K., Yamanda T., Haniuda M., Honda T. Pulmonary artery remodeling modifies pulmonary hypertension during exercise in severe emphysema. Respir Physiol. 2000 Mar;120(1):71–79. doi: 10.1016/s0034-5687(00)00090-6. [DOI] [PubMed] [Google Scholar]
  13. Liu S. Q., Fung Y. C. Changes in the structure and mechanical properties of pulmonary arteries of rats exposed to cigarette smoke. Am Rev Respir Dis. 1993 Sep;148(3):768–777. doi: 10.1164/ajrccm/148.3.768. [DOI] [PubMed] [Google Scholar]
  14. Loscalzo J. Endothelial dysfunction in pulmonary hypertension. N Engl J Med. 1992 Jul 9;327(2):117–119. doi: 10.1056/NEJM199207093270209. [DOI] [PubMed] [Google Scholar]
  15. MacNee W. Pathophysiology of cor pulmonale in chronic obstructive pulmonary disease. Part One. Am J Respir Crit Care Med. 1994 Sep;150(3):833–852. doi: 10.1164/ajrccm.150.3.8087359. [DOI] [PubMed] [Google Scholar]
  16. Oswald-Mammosser M., Weitzenblum E., Quoix E., Moser G., Chaouat A., Charpentier C., Kessler R. Prognostic factors in COPD patients receiving long-term oxygen therapy. Importance of pulmonary artery pressure. Chest. 1995 May;107(5):1193–1198. doi: 10.1378/chest.107.5.1193. [DOI] [PubMed] [Google Scholar]
  17. Ozaki M., Kawashima S., Yamashita T., Ohashi Y., Rikitake Y., Inoue N., Hirata K. I., Hayashi Y., Itoh H., Yokoyama M. Reduced hypoxic pulmonary vascular remodeling by nitric oxide from the endothelium. Hypertension. 2001 Feb;37(2):322–327. doi: 10.1161/01.hyp.37.2.322. [DOI] [PubMed] [Google Scholar]
  18. Partovian C., Adnot S., Raffestin B., Louzier V., Levame M., Mavier I. M., Lemarchand P., Eddahibi S. Adenovirus-mediated lung vascular endothelial growth factor overexpression protects against hypoxic pulmonary hypertension in rats. Am J Respir Cell Mol Biol. 2000 Dec;23(6):762–771. doi: 10.1165/ajrcmb.23.6.4106. [DOI] [PubMed] [Google Scholar]
  19. Pauwels R. A., Buist A. S., Ma P., Jenkins C. R., Hurd S. S., GOLD Scientific Committee Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: National Heart, Lung, and Blood Institute and World Health Organization Global Initiative for Chronic Obstructive Lung Disease (GOLD): executive summary. Respir Care. 2001 Aug;46(8):798–825. [PubMed] [Google Scholar]
  20. Rabinovitch M. Pathobiology of pulmonary hypertension. Extracellular matrix. Clin Chest Med. 2001 Sep;22(3):433-49, viii. doi: 10.1016/s0272-5231(05)70282-3. [DOI] [PubMed] [Google Scholar]
  21. Roland M., Bhowmik A., Sapsford R. J., Seemungal T. A., Jeffries D. J., Warner T. D., Wedzicha J. A. Sputum and plasma endothelin-1 levels in exacerbations of chronic obstructive pulmonary disease. Thorax. 2001 Jan;56(1):30–35. doi: 10.1136/thorax.56.1.30. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Rubin Lewis J., Badesch David B., Barst Robyn J., Galie Nazzareno, Black Carol M., Keogh Anne, Pulido Tomas, Frost Adaani, Roux Sebastien, Leconte Isabelle. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002 Mar 21;346(12):896–903. doi: 10.1056/NEJMoa012212. [DOI] [PubMed] [Google Scholar]
  23. Santos Salud, Peinado Victor I., Ramirez Josep, Morales-Blanhir Jaime, Bastos Ricardo, Roca Josep, Rodriguez-Roisin Robert, Barbera Joan A. Enhanced expression of vascular endothelial growth factor in pulmonary arteries of smokers and patients with moderate chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2003 Feb 20;167(9):1250–1256. doi: 10.1164/rccm.200210-1233OC. [DOI] [PubMed] [Google Scholar]
  24. Scharf Steven M., Iqbal Mobeen, Keller Cesar, Criner Gerald, Lee Shing, Fessler Henry E., National Emphysema Treatment Trial (NETT) Group Hemodynamic characterization of patients with severe emphysema. Am J Respir Crit Care Med. 2002 Aug 1;166(3):314–322. doi: 10.1164/rccm.2107027. [DOI] [PubMed] [Google Scholar]
  25. Smith Adrian P. L., Demoncheaux Eric A. G., Higenbottam Tim W. Nitric oxide gas decreases endothelin-1 mRNA in cultured pulmonary artery endothelial cells. Nitric Oxide. 2002 Mar;6(2):153–159. doi: 10.1006/niox.2001.0400. [DOI] [PubMed] [Google Scholar]
  26. Steudel W., Ichinose F., Huang P. L., Hurford W. E., Jones R. C., Bevan J. A., Fishman M. C., Zapol W. M. Pulmonary vasoconstriction and hypertension in mice with targeted disruption of the endothelial nitric oxide synthase (NOS 3) gene. Circ Res. 1997 Jul;81(1):34–41. doi: 10.1161/01.res.81.1.34. [DOI] [PubMed] [Google Scholar]
  27. Unemori E. N., Ferrara N., Bauer E. A., Amento E. P. Vascular endothelial growth factor induces interstitial collagenase expression in human endothelial cells. J Cell Physiol. 1992 Dec;153(3):557–562. doi: 10.1002/jcp.1041530317. [DOI] [PubMed] [Google Scholar]
  28. Weitzenblum E., Hirth C., Ducolone A., Mirhom R., Rasaholinjanahary J., Ehrhart M. Prognostic value of pulmonary artery pressure in chronic obstructive pulmonary disease. Thorax. 1981 Oct;36(10):752–758. doi: 10.1136/thx.36.10.752. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Weitzenblum E., Sautegeau A., Ehrhart M., Mammosser M., Hirth C., Roegel E. Long-term course of pulmonary arterial pressure in chronic obstructive pulmonary disease. Am Rev Respir Dis. 1984 Dec;130(6):993–998. doi: 10.1164/arrd.1984.130.6.993. [DOI] [PubMed] [Google Scholar]
  30. Wright J. L., Farmer S. G., Churg A. A neutrophil elastase inhibitor reduces cigarette smoke-induced remodelling of lung vessels. Eur Respir J. 2003 Jul;22(1):77–81. doi: 10.1183/09031936.03.00095703. [DOI] [PubMed] [Google Scholar]
  31. Wright J. L., Lawson L., Paré P. D., Hooper R. O., Peretz D. I., Nelems J. M., Schulzer M., Hogg J. C. The structure and function of the pulmonary vasculature in mild chronic obstructive pulmonary disease. The effect of oxygen and exercise. Am Rev Respir Dis. 1983 Oct;128(4):702–707. doi: 10.1164/arrd.1983.128.4.702. [DOI] [PubMed] [Google Scholar]
  32. Wright J. L., Petty T., Thurlbeck W. M. Analysis of the structure of the muscular pulmonary arteries in patients with pulmonary hypertension and COPD: National Institutes of Health nocturnal oxygen therapy trial. Lung. 1992;170(2):109–124. doi: 10.1007/BF00175982. [DOI] [PubMed] [Google Scholar]
  33. Wright J. L. Relationship of pulmonary arterial pressure and airflow obstruction to emphysema. J Appl Physiol (1985) 1993 Mar;74(3):1320–1324. doi: 10.1152/jappl.1993.74.3.1320. [DOI] [PubMed] [Google Scholar]
  34. Wright Joanne L., Tai Hsin, Churg Andrew. Cigarette smoke induces persisting increases of vasoactive mediators in pulmonary arteries. Am J Respir Cell Mol Biol. 2004 Jul 8;31(5):501–509. doi: 10.1165/rcmb.2004-0051OC. [DOI] [PubMed] [Google Scholar]
  35. Wright Joanne L., Tai Hsin, Dai Jin, Churg Andrew. Cigarette smoke induces rapid changes in gene expression in pulmonary arteries. Lab Invest. 2002 Oct;82(10):1391–1398. doi: 10.1097/01.lab.0000032806.45023.08. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES